Clinical trials: Respiratory Changes
- Condition Respiratory Changes
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Lung Cancer
NovellusDx Cancer Early Detection Blood Test- Clinical Trial
NovellusDx early detection test is a simple to perform blood test, which identifies the deregulated signaling pathways within the patient tumor based on protein secretion to the blood, thus enabling early stage disease signature…
- Trial name
- NCT01883388
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fore Biotherapeutics
Influenza (Healthy Volunteers)
Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea
To describe the immune response induced by quadrivalent recombinant influenza vaccine (RIV4) and Quadrivalent-inactivated Influenza Vaccine (IIV4) in 18-49 and greater than or equal to (>=) 50 years of age participants by…
- Trial name
- NCT05144945
- Testing
- Quadrivalent Recombinant Influenza Vaccine (RIV4), Quadrivalent inactivated influenza vaccine (IIV4)
- Where
- 3 sites in South Korea
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.
A safety study to compare, over a 7 day period, the fever rates following one dose of either Influenza Virus Vaccine or placebo administered outside the influenza season to healthy children and adolescents aged 6 to less than 18…
- Trial name
- FluMist (NCT00192179)
- Testing
- Cold-adapted influenza vaccine trivalent (CAIV-T)
- Where
- 6 sites in Belgium, Poland and 1 more
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
A Randomized, Open-Label, Two-Period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Chinese Subjects under Fed Conditions Primary objective…
- Trial name
- NCT06588517
- Testing
- Pirfenidone Modified-Release Tablets, Pirfenidone Tablets
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Influenza
A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
The pivotal Phase 3 trial plans to enroll a total of approximately 12,460 participants aged 50+ over two years. Participants will be immunized twice with the M-001 universal influenza vaccine candidate or placebo and then…
- Trial name
- NCT03450915
- Testing
- M-001, Saline
- Where
- 2 sites in Poland
- Volunteers
- 12,460 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age.
- Trial name
- NCT06641180
- Testing
- High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
- Where
- 20 sites in United States
- Volunteers
- 1,180 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1.
- Trial name
- NCT01773928
- Testing
- Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV)
- Where
- 20 sites in United States
- Volunteers
- 1,928 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
SARS-CoV-2 Infections
A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults
This is a Phase 1, open-label, randomized, 2-period, 2-sequence, cross-over study to estimate the effect of ibuzatrelvir on the PK of dabigatran, a P-gp substrate, in healthy adult participants.
- Trial name
- NCT06693518
- Testing
- Treatment B, Treatment A
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
COPD, Asthma
Cardiorespiratory Diagnostic Study
This study uses a new breathing device called 'N-Tidal C' handset which measures breathing patterns. Investigators have found that people with cardiac and respiratory illnesses breathe out a gas, called carbon dioxide (CO2), in a…
- Conditions
- COPD, Asthma, Lung Cancer, Anemia
- Trial name
- CARES (NCT04939558)
- Testing
- N-Tidal C handset
- Where
- United Kingdom
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- TidalSense
COVID-19 Vaccines
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age.
- Trial name
- NCT07730450
- Testing
- BNT162b2 Vaccine, Tdap Vaccine
- Where
- 5 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Influenza, Human
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza…
- Trial name
- NCT05540522
- Testing
- Quadrivalent influenza modRNA vaccine, Quadrivalent influenza vaccine
- Where
- 321 sites in United States, Argentina and 4 more
- Volunteers
- 45,789 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695130
- Testing
- RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults
To perform a variety of assays on blood, serum, nasal wash samples and cells obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by…
- Trial name
- NCT00192192
- Testing
- CAIV-T
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Human, SARS-CoV-2 Infection
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the…
- Conditions
- Influenza, Human, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT06237049
- Testing
- BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV
- Where
- 30 sites in United States
- Volunteers
- 644 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cold, Cold Symptom
Ability of Beta-glucan Supplementation to Augment Immune Function
This proposed study is designed to assess the efficacy of a capsule containing beta-glucan taken orally daily as compared to a placebo capsule on the URTI symptoms, and the immune response change in marathon runners
- Conditions
- Cold, Cold Symptom, Flu, Flu Symptom
- Trial name
- NCT03769012
- Testing
- Beta-Glucan
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kemin Foods LC
Healthy Participants
A Study of IVX-A12 in Adults Participants
The primary purpose of this study is to assess the immunogenicity and safety of IVX-A12 in adults 60 years of age and older.
- Trial name
- NCT06481579
- Testing
- IVX-A12, Licensed RSV Vaccine
- Where
- 5 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Icosavax, Inc.
Heart Failure, Congestive
Evaluation of MRI Measures of Lung Water With Posture Changes in Healthy Volunteers and in Patients With Cardiac Failure
The aim of this study is to establish a model for the evaluation of drug targets using postural measures to induce changes in lung water concentration as assessed by MRI.
- Trial name
- NCT01277679
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Immunization
Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above
This is a Phase 1, parallel, randomized, active-controlled, multi-center, dose-esclation study with a Master Protocol design which will include several substudies that are developed to evaluate the safety and immunogenicity of…
- Trial name
- NCT05829356
- Testing
- H3 mRNA / LNP Vaccine, Quadrivalent recombinant influenza Vaccine (RIV4)
- Where
- 8 sites in Australia, United Kingdom
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infections
RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.
In this study we are testing a new vaccine against Respiratory Syncytial Virus (RSV). This virus can cause respiratory infections such as bronchiolitis and pneumonia.
- Trial name
- NCT01805921
- Testing
- PanAd3-RSV given intra-nasally (high dose), MVA-RSV given by intra-muscular injection (high dose), PanAd3-RSV given by intra-muscular injection (high dose)
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- ReiThera Srl
COVID-19 Vaccines
A Study of COVID-19 Vaccine(s) in Children and Adults
The purpose of this study is to learn about the safety and effects of updated COVID-19 vaccines (called BNT162b2) in participants 5 Through 64 Years of Age with risk factors for Severe COVID-19, and Participants 65 Years of Age…
- Trial name
- NCT07798648
- Testing
- BNT162b2
- Where
- 14 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- BioNTech SE